2020
The association between Medicaid insurance, biomarker testing, and outcomes in patients with advanced non-small cell lung cancer (aNSCLC).
Gross C, Meyer C, Ogale S, Kent M, Wong W. The association between Medicaid insurance, biomarker testing, and outcomes in patients with advanced non-small cell lung cancer (aNSCLC). Journal Of Clinical Oncology 2020, 38: 89-89. DOI: 10.1200/jco.2020.38.29_suppl.89.Peer-Reviewed Original ResearchBiomarker-driven therapiesBiomarker testingEvidence of testingYear of diagnosisQuality cancer careUS cancer patientsLikelihood of testingDe-identified databaseEvidence of receiptEligible ptsOverall survivalAdjusted analysisContemporary cohortMedicaid insuranceRetrospective studyCancer careCancer patientsWorse outcomesCancer clinicHigh riskCommercial insurancePrivate insuranceAdvanced diagnosisTherapyDiagnosis
2017
Disparities in next generation sequencing in a population-based community cohort of patients with advanced non-small cell lung cancer.
Presley C, Soulos P, Chiang A, Longtine J, Adelson K, Herbst R, Nussbaum N, Sorg R, Abernethy A, Agarwala V, Gross C. Disparities in next generation sequencing in a population-based community cohort of patients with advanced non-small cell lung cancer. Journal Of Clinical Oncology 2017, 35: 6563-6563. DOI: 10.1200/jco.2017.35.15_suppl.6563.Peer-Reviewed Original ResearchNon-small cell lung cancerAdvanced non-small cell lung cancerCell lung cancerNGS testingLung cancerBiomarker testingOncology practiceNext-generation sequencingNon-squamous non-small cell lung cancerPopulation-based community cohortReal-world clinical practiceMulti-gene panel testingInsurance-related disparitiesAdvanced lung cancerFirst-line treatmentHistory of smokingRetrospective observational studyElectronic health record dataWorld clinical practiceClustering of patientsHealth record dataYounger patientsMedian agePatient characteristicsWhite patients